NCT05361395 2026-03-03First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)AmgenPhase 1 Active not recruiting184 enrolled
NCT03843359 2026-01-08A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid TumorsGlaxoSmithKlinePhase 1 Active not recruiting97 enrolled 45 charts